EMEA-001084-PIP01-10 - paediatric investigation plan

rivastigmine

Key facts

• Invented name:
  • Exelon
  • Exelon
• Active Substance:
  rivastigmine
• Therapeutic area:
  Neurology
• Decision number:
  P/65/2011
• PIP number:
  EMEA-001084-PIP01-10
• Pharmaceutical form(s):
  Transdermal patch
• Condition(s) / indication(s):
  Treatment of dementia
• Route(s) of administration:
  Transdermal use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  11/03/2011

Decision

P/65/2011: EMA decision of 11 March 2011 on the granting of a product specific waiver for rivastigmine, (EMEA-001084-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

AdoptedReference Number: EMA/170473/2011